These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 36747539)

  • 1. Multi-head self-attention mechanism enabled individualized hemoglobin prediction and treatment recommendation systems in anemia management for hemodialysis patients.
    Yang JY; Lee TC; Liao WT; Hsu CC
    Heliyon; 2023 Feb; 9(2):e12613. PubMed ID: 36747539
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Physician Compliance With a Computerized Clinical Decision Support System for Anemia Management of Patients With End-stage Kidney Disease on Hemodialysis: Retrospective Electronic Health Record Observational Study.
    Yang JY; Shu KH; Peng YS; Hsu SP; Chiu YL; Pai MF; Wu HY; Tsai WC; Tung KT; Kuo RN
    JMIR Form Res; 2023 May; 7():e44373. PubMed ID: 37133912
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Performance of a Predictive Model for Long-Term Hemoglobin Response to Darbepoetin and Iron Administration in a Large Cohort of Hemodialysis Patients.
    Barbieri C; Bolzoni E; Mari F; Cattinelli I; Bellocchio F; Martin JD; Amato C; Stopper A; Gatti E; Macdougall IC; Stuard S; Canaud B
    PLoS One; 2016; 11(3):e0148938. PubMed ID: 26939055
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Switch of ESA therapy from darbepoetin-alpha to epoetin-beta in hemodialysis patients: a single-center experience.
    Biggar P; Ketteler M; Hennemann H; Dömling R
    Clin Nephrol; 2008 Mar; 69(3):185-92. PubMed ID: 18397717
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Long-Term Safety of C.E.R.A. Maintenance in Pediatric Hemodialysis Patients with Anemia of CKD.
    Fischbach M; Wühl E; Reigner SCM; Morgan Z; Schaefer F
    Clin J Am Soc Nephrol; 2018 Jan; 13(1):81-90. PubMed ID: 29097481
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Darbepoetin alfa injection versus epoetin alfa injection for treating anemia of Chinese hemodialysis patients with chronic kidney failure: A randomized, open-label, parallel-group, non-inferiority Phase III trail.
    Chen N; Xing C; Niu J; Liu B; Fu J; Zhao J; Ni Z; Wang M; Liu W; Zhao J; Zhong L; Wu X; Li W; Chen Y; Shi W; Chen J; Yin A; Fu P; Wang R; Jiang G; Hou F; Ding G; Chen J; Xu G; Kondo Y; Su Y; Mei C
    Chronic Dis Transl Med; 2022 Mar; 8(1):59-70. PubMed ID: 35620165
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Erythropoiesis stimulating agent recommendation model using recurrent neural networks for patient with kidney failure with replacement therapy.
    Yun HR; Lee G; Jeon MJ; Kim HW; Joo YS; Kim H; Chang TI; Park JT; Han SH; Kang SW; Kim W; Yoo TH
    Comput Biol Med; 2021 Oct; 137():104718. PubMed ID: 34481182
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
    Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
    Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Types of Erythropoietin-Stimulating Agents and Mortality among Patients Undergoing Hemodialysis.
    Sakaguchi Y; Hamano T; Wada A; Masakane I
    J Am Soc Nephrol; 2019 Jun; 30(6):1037-1048. PubMed ID: 31015255
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Indole 3-acetic acid, indoxyl sulfate and paracresyl-sulfate do not influence anemia parameters in hemodialysis patients.
    Bataille S; Pelletier M; Sallée M; Berland Y; McKay N; Duval A; Gentile S; Mouelhi Y; Brunet P; Burtey S
    BMC Nephrol; 2017 Jul; 18(1):251. PubMed ID: 28747155
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of erythropoiesis-stimulating agents among chemotherapy patients with hemoglobin exceeding 12 grams per deciliter.
    Nordstrom BL; Luo W; Fraeman K; Whyte JL; Nordyke RJ
    J Manag Care Pharm; 2008; 14(9):858-69. PubMed ID: 19006442
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Model predictive control of erythropoietin administration in the anemia of ESRD.
    Gaweda AE; Jacobs AA; Aronoff GR; Brier ME
    Am J Kidney Dis; 2008 Jan; 51(1):71-9. PubMed ID: 18155535
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patterns of Erythropoiesis-Stimulating Agent Use in European Hemodialysis Patients: The Dialysis Outcomes and Practice Patterns Study.
    Fuller DS; Robinson BM; Locatelli F; Pisoni RL
    Nephron; 2018; 140(1):24-30. PubMed ID: 29945128
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current management of anemia in adult hemodialysis patients with end-stage renal disease.
    Frankenfield DL; Johnson CA
    Am J Health Syst Pharm; 2002 Mar; 59(5):429-35. PubMed ID: 11887409
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Individualized anemia management reduces hemoglobin variability in hemodialysis patients.
    Gaweda AE; Aronoff GR; Jacobs AA; Rai SN; Brier ME
    J Am Soc Nephrol; 2014 Jan; 25(1):159-66. PubMed ID: 24029429
    [TBL] [Abstract][Full Text] [Related]  

  • 16. International Comparisons to Assess Effects of Payment and Regulatory Changes in the United States on Anemia Practice in Patients on Hemodialysis: The Dialysis Outcomes and Practice Patterns Study.
    Fuller DS; Bieber BA; Pisoni RL; Li Y; Morgenstern H; Akizawa T; Jacobson SH; Locatelli F; Port FK; Robinson BM
    J Am Soc Nephrol; 2016 Jul; 27(7):2205-15. PubMed ID: 26582402
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Opatija study: observation of hemodialysis patients and titration of CERA dose just switched from another erythropoiesis stimulating agent].
    Jelić I; Lovcić V; Kurtović I; Josipović M; Havranek Z; Kostić L; Racki S
    Acta Med Croatica; 2012 Jul; 66(3):157-64. PubMed ID: 23441529
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Darbepoetin alfa for treating chemotherapy-induced anemia in patients with a baseline hemoglobin level < 10 g/dL versus > or = 10 g/dL: an exploratory analysis from a randomized, double-blind, active-controlled trial.
    Vansteenkiste J; Hedenus M; Gascon P; Bokemeyer C; Ludwig H; Vermorken J; Hamilton L; Bridges K; Pujol B
    BMC Cancer; 2009 Sep; 9():311. PubMed ID: 19728887
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Individualized anemia management in a dialysis facility - long-term utility as a single-center quality improvement experience
.
    Gaweda AE; Jacobs AA; Aronoff GR; Brier ME
    Clin Nephrol; 2018 Oct; 90(4):276-285. PubMed ID: 30049300
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inflammation and Erythropoiesis-Stimulating Agent Response in Hemodialysis Patients: A Self-matched Longitudinal Study of Anemia Management in the Dialysis Outcomes and Practice Patterns Study (DOPPS).
    Karaboyas A; Morgenstern H; Fleischer NL; Vanholder RC; Dhalwani NN; Schaeffner E; Schaubel DE; Akizawa T; James G; Sinsakul MV; Pisoni RL; Robinson BM
    Kidney Med; 2020; 2(3):286-296. PubMed ID: 32734248
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.